Medtronic received FDA approval for the first leadless pacemaker in 2016, but faces a new competitor in Abbott, which got the nod for its own leadless device last year.
Medtronic ramps up competition for leadless pacemakers with newly approved devices Read More »
The tech giant is exiting the wearables sector as it eliminates 27,000 jobs this year. Amazon’s Halo devices will stop working on Aug. 1.
Amazon closes Halo health tracking unit as wave of tech layoffs continues Read More »
The move, if completed, would mean the end of the company as a health insurer.
Bright Health explores sale of California MA business Read More »
About half of nurses polled by AMN Healthcare said they were likely to encourage others to take up the profession in 2023, down from 64% in 2021.
The extended timeline to create a new regulatory system in England, Scotland and Wales is intended to prevent medical device shortages.
Great Britain proposes allowing CE marks until 2030 to minimize Brexit disruption Read More »
As it eliminates 27,000 jobs this year, the tech giant is exiting the wearables sector, and its Halo devices will stop working on Aug. 1.
Amazon closes Halo health tracking unit as wave of tech layoffs continues Read More »
Lipella Pharmaceuticals Inc. today announced that it has delivered a late-breaking presentation at the annual meeting of the American Urological Association (AUA) Annual Meeting in Chicago on April 30, 2023.
Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.
Crown Therapeutics, a division of Crown Laboratories, is proud to announce that PanOxyl® is expanding its award-winning portfolio with its new PM Balancing Repair Moisturizer and reformulating the existing AM Oil Control Moisturizer.
CG Oncology, Inc. announced updated data from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
